dendrit
cell
dc
famili
profession
antigenpres
cell
apc
abl
initi
innat
adapt
immun
respons
pathogen
tumor
cell
dc
famili
heterogen
classic
divid
two
main
subset
uniqu
phenotyp
function
characterist
myeloid
dc
mdc
plasmacytoid
dc
pdc
recent
result
provid
intrigu
evid
dc
subset
also
function
direct
cytotox
effector
cell
particular
cancer
cell
review
delv
understudi
function
human
dc
discuss
socal
killer
dc
might
becom
import
tool
futur
cancer
immunotherapi
dc
commandersinchief
immun
armi
forti
year
discoveri
zanvil
cohn
ralph
steinman
dc
continu
fascin
intrigu
immunologist
although
nomenclatur
dc
system
still
evolv
novel
marker
identifi
subclassifi
dc
continu
identifi
well
establish
dc
famili
constitut
heterogen
group
cell
categor
two
main
subtyp
mdc
pdc
despit
consider
heterogen
differ
dc
type
term
phenotyp
gene
express
profil
function
common
characterist
dc
capac
antigen
present
uniqu
abil
prime
activ
lymphocyt
primari
apc
immun
system
dc
pivot
elicit
adapt
immun
respons
determin
balanc
immun
toler
addit
central
role
adapt
immun
dc
also
occupi
preemin
place
within
innat
immun
system
context
dc
express
tolllik
receptor
tlr
famili
innat
immun
receptor
involv
sens
virus
microbi
stimuli
dc
also
capabl
activ
innat
immun
cell
includ
natur
killer
nk
cell
given
key
role
regul
innat
adapt
immun
dc
critic
induct
antitumor
immun
role
induct
antigenspecif
cytotox
lymphocyt
ctl
capac
har
cytotox
activ
innat
immun
cell
nk
cell
nkt
cell
gd
cell
dc
elicit
potent
cytotox
immun
respons
toward
tumor
cell
evid
anim
human
studi
indic
dc
initi
cytotox
effector
function
directli
contribut
tumor
cell
kill
socal
killer
dc
first
describ
popul
murin
dc
identifi
capac
lyse
cell
ligand
fasl
depend
fashion
almost
one
decad
later
three
research
group
independ
report
exist
novel
dc
type
within
murin
immun
system
bore
phenotyp
molecular
function
characterist
dc
nk
cell
dc
subtyp
term
natur
killer
dendrit
cell
nkdc
altern
interferonproduc
killer
dc
ikdc
nk
celllik
properti
cytotox
activ
capac
produc
high
amount
interferon
ifn
g
although
nkdc
capabl
antigen
process
present
soon
becam
appar
term
actual
misnom
nkdc
belong
nk
cell
lineag
dc
lineag
appar
erron
terminolog
led
confus
even
skeptic
actual
exist
killer
dc
recent
studi
howev
provid
substanti
evid
direct
cytotox
effector
function
dc
killer
dc
identifi
rodent
human
appear
constitut
heterogen
popul
cell
follow
characterist
common
endow
direct
cytolyt
potenti
ii
fulfil
phenotyp
function
criteria
classifi
bona
fide
dc
iii
defin
nk
cell
despit
cytotox
activ
eg
absenc
classic
nk
cell
surfac
marker
target
cell
profil
differ
nk
cell
summar
find
accumul
recent
year
killer
dc
discuss
potenti
relev
cell
futur
immunotherapi
strategi
major
differ
mode
action
identifi
rodent
human
killer
dc
exist
function
rodent
killer
dc
excel
review
elsewher
focu
discuss
killer
dc
human
monocyt
monocytederiv
dc
modc
killer
cell
immatur
dc
resid
mostli
part
bodi
close
contact
outsid
world
skin
mucos
tissu
abl
quickli
sens
take
pathogen
could
harm
host
pathogen
recognit
dc
matur
migrat
lymphoid
tissu
present
pathogen
peptid
cell
modc
far
wide
use
cell
type
studi
human
dc
ex
vivo
tabl
although
varieti
protocol
exist
gener
modc
basic
procedur
consist
two
phase
monocyt
differenti
immatur
dc
use
combin
cytokin
eg
granulocytemacrophag
colonystimul
factor
gmcsf
interleukin
il
ifna
ii
modc
matur
induc
activ
stimuli
eg
proinflammatori
cytokin
tlr
ligand
immatur
dc
exploit
wide
varieti
pattern
recognit
receptor
recogn
take
antigen
sever
differenti
matur
agent
trigger
human
modc
acquir
cytotox
effector
function
differ
studi
suggest
cytolyt
potenti
alreadi
resid
monocyt
precursor
cell
compart
tabl
inde
human
well
monocyt
stimul
type
ii
ifn
ligand
lipopolysaccharid
lp
ligand
shown
exert
antitumor
activ
rang
cancer
cell
line
tabl
three
studi
tnfarel
apoptosisinduc
ligand
trail
implic
direct
tumoricid
activ
human
monocyt
traildepend
apoptosi
also
report
play
role
cytotox
activ
human
modc
virus
includ
measl
viru
cytomegaloviru
cmv
tlr
ligand
doublestrand
rna
type
ifn
matur
agent
capabl
induc
trail
express
modc
tabl
convers
anoth
studi
found
ligat
inhibit
trail
express
modc
cytotox
abil
modc
preserv
suggest
trailindepend
mechan
induct
cell
death
inde
outlin
tabl
cell
contactdepend
independ
mechan
implic
modcmedi
kill
cytolyt
armamentarium
includ
addit
trail
broad
rang
cytotox
effector
molecul
tnfa
fasl
lymphotoxin
lt
tnflike
weak
induc
apoptosi
tweak
ifng
granzym
b
program
death
ligand
major
studi
killer
modc
focus
tumoricid
potenti
modc
capabl
exert
cytotox
broad
rang
tumor
cell
line
spare
normal
cell
tabl
reason
appar
tumorselect
action
remain
incomplet
understood
although
express
decoy
receptor
eg
trail
decoy
receptor
activ
antiapoptot
mechan
eg
upregul
cellular
faddlik
enzym
proteaseinhibitori
protein
cflip
may
help
explain
normal
cell
larg
resist
kill
modc
despit
seemingli
preferenti
tumordirect
action
certain
circumst
modc
induc
cell
death
observ
made
sever
studi
tabl
perform
context
infecti
diseas
first
studi
demonstr
modc
infect
measl
viru
induc
paracrin
kill
autolog
cell
monocyt
modc
expos
capabl
induc
apoptosi
well
noninfect
cell
either
allogen
autolog
origin
anoth
studi
shown
lpsmatur
modc
deriv
tuberculosi
patient
increas
express
underlin
antiprolif
proapoptot
activ
toward
cell
similarli
lpsmatur
modc
gener
chronic
hepat
c
patient
found
lyse
healthi
allogen
well
patientderiv
autolog
cell
fasldepend
fashion
taken
togeth
find
indic
human
monocyt
modc
appropri
stimul
function
cytotox
antitumor
effector
context
chronic
infect
also
immunoregulatori
cell
cell
kill
activ
although
observ
ex
vivo
gener
modc
act
direct
killer
cell
interest
anoth
relev
question
whether
also
applic
natur
circul
dc
although
studi
use
modc
sever
studi
delv
killer
function
blood
dc
shown
two
main
blood
dc
subset
mdc
pdc
cytotox
human
blood
mdc
subset
usual
defin
lineag
lin
hladr
dim
cell
blood
mdc
subdivid
nonoverlap
subset
base
express
blood
dendrit
cell
antigen
bdca
classic
mdc
remain
immatur
state
migrat
peripher
tissu
lymph
node
matur
activ
cell
cytotox
potenti
hitherto
report
total
mdc
popul
well
subset
tabl
first
descript
direct
cytotox
activ
human
blood
mdc
date
back
late
mdc
stimul
ifna
ifng
directli
lyse
variou
tumor
cell
line
traildepend
fashion
trail
also
implic
blood
dcmediat
cytotox
two
studi
tabl
contrast
trail
seem
import
mediat
cytotox
tlractiv
mdc
recent
studi
show
neither
mdc
produc
trail
exposur
tlr
ligand
line
observ
tumorinfiltr
mdc
express
secret
perforin
granzym
b
trail
upon
stimul
trend
immunolog
januari
vol
granzym
b
also
implic
mdcmediat
apoptosi
mdc
taken
togeth
data
illustr
killer
mdc
like
vitro
modc
counterpart
exploit
varieti
cytotox
effector
mechan
exert
kill
function
tabl
similar
modc
studi
killer
function
nativ
blood
mdc
perform
use
tumor
cell
line
target
cell
abil
blood
mdc
kill
cell
examin
one
studi
show
lpsactiv
mdc
chronic
hepat
c
patient
induc
lysi
autolog
patient
cell
well
allogen
healthi
cell
fasland
fashion
tabl
studi
provid
evid
abil
nativ
blood
mdc
kill
cell
chronic
viral
infect
mechan
may
exploit
virus
escap
antivir
cell
pdc
killer
cell
pdc
defin
lin
cell
addit
marker
immunoglobulinlik
transcript
ilt
restrict
pdc
peripher
blood
bone
marrow
function
level
human
pdc
differ
dc
subset
abil
produc
larg
amount
type
ifn
upon
ligat
viral
bacteri
compon
pdc
gener
found
circul
peripheri
howev
infiltr
tissu
case
infect
inflamm
tumor
like
myeloid
counterpart
pdc
also
describ
exert
direct
cytotox
function
figur
tabl
exampl
human
pdc
cell
line
capabl
lyse
tumor
cell
partli
traildepend
manner
stimul
inactiv
influenza
viru
type
ifn
tabl
pdc
cell
line
express
nk
cell
surfac
mark
wherea
nk
cell
marker
absent
pdc
activ
tickborn
enceph
vaccin
fmse
also
upregul
wherea
sever
tlr
agonist
induc
upregul
pdc
express
high
amount
trail
granzym
b
neither
cytotox
molecul
requir
observ
cytotox
nevertheless
kill
capac
depend
celltocel
contact
wherebi
fsmepdc
specif
lyse
mhcclassineg
tumor
cell
line
daudi
mhc
class
posit
cell
line
contrast
pdc
stimul
imiquimod
agonist
lesser
extend
agonist
cpg
ifna
kill
mhcclassiposit
tumor
cell
trailand
contactdepend
manner
although
trail
appear
import
mediat
pdcmediat
cytotox
cytotox
effector
molecul
implic
tabl
shown
differ
cytotox
effector
molecul
express
blood
pdc
includ
trail
granzym
b
lysozym
high
lysozym
express
high
pdc
subset
observ
although
relat
increas
cytotox
activ
high
pdc
compar
low
counterpart
import
note
high
lysozym
express
high
pdc
subset
could
confirm
anoth
independ
perform
studi
indic
mechan
superior
abil
chronic
hepat
c
patient
c
abbrevi
adcc
antibodydepend
cellmedi
cytotox
cb
cord
blood
e
ratio
effector
cell
target
cell
ratio
fadd
fasassoci
protein
death
domain
hpv
human
papillomaviru
nd
determin
pb
peripher
blood
tgf
transform
growth
factor
trend
immunolog
januari
vol
high
pdc
low
pdc
bind
target
might
involv
cytotox
action
high
pdc
express
granzym
b
observ
unstimul
pdc
well
pdc
stimul
andor
molecul
seem
contribut
cytotox
stimul
pdc
granzymebproduc
pdc
target
cell
granzymebdepend
perforinindepend
manner
confirm
find
other
killer
dc
mediat
cytotox
granzym
pathway
complet
devoid
perforin
apart
granzym
b
trail
also
implic
mediat
cell
lysi
pdc
pdc
stimul
purifi
human
cell
leukemia
viru
htlv
upregul
trail
induc
traildepend
apoptosi
primari
cell
cell
line
pathway
endosom
degrad
involv
transform
pdc
killer
variant
agreement
pdc
isol
virem
hiv
patient
express
trail
induc
apoptosi
hivinfect
cell
anoth
studi
trail
pdc
trend
immunolog
januari
vol
display
cytotox
respons
hivinfect
autolog
cell
capabl
induc
apoptosi
hivinfect
cell
line
abil
human
killer
pdc
induc
apoptosi
virusinfect
cell
may
protect
mechan
host
immun
system
control
viru
spread
killer
dc
war
cancer
indirect
cytotox
effect
pdcderiv
type
ifn
pdc
gener
accept
major
type
ifnproduc
cell
immun
system
type
ifn
initi
protect
immun
matur
mdc
subsequ
activ
cell
nk
cell
review
therebi
pdc
may
play
central
role
induc
indirect
cytotox
activ
tumor
via
variou
pathway
exampl
apoptosi
induct
antiangiogenesi
via
signal
common
ifna
receptor
furthermor
direct
inhibitori
effect
tumor
cell
growthfunct
thought
major
mechan
antitumor
respons
ifntreat
patient
fact
ifna
directli
inhibit
prolifer
tumor
cell
vitro
vivo
exert
direct
effect
tumor
cell
figur
next
direct
cytotox
cytostat
effect
ifna
also
wide
stimulatori
effect
immun
cell
discuss
monocyt
differenti
killer
dc
control
ifna
addit
recent
studi
shown
ifna
also
improv
mdc
surviv
capac
store
process
exogen
antigen
lead
enhanc
crosspresent
crossprim
antigenspecif
cell
respons
vivo
evid
recent
provid
two
independ
studi
show
mice
type
ifn
critic
induct
antitumor
immun
respons
furthermor
type
ifn
regul
nk
cell
function
enhanc
nk
cell
kill
target
cell
produc
ifng
also
type
ifn
promot
accumul
andor
surviv
prolifer
nk
cell
type
ifn
signal
transduc
activ
transcript
stat
induct
studi
suggest
upon
activ
pdc
exert
wide
varieti
indirect
cytotox
antitumor
effect
figur
notion
underscor
studi
demonstr
either
pdc
ifna
deplet
lead
loss
trailmedi
tumor
cell
kill
monocyt
highlight
crucial
role
pdcderiv
ifna
antitumor
immun
express
trail
wide
varieti
immun
cell
known
regul
type
ifn
moreov
studi
even
direct
link
pdcderiv
type
ifn
trail
express
target
kill
context
hiv
whether
killer
pdc
also
acquir
trail
express
report
condit
para
trend
immunolog
januari
vol
crine
autocrin
typeiifndepend
manner
remain
determin
discoveri
abil
dc
becom
tumor
cell
killer
gener
new
opportun
futur
nonconvent
immunotherapeut
strategi
gener
accept
macrophag
dc
outnumb
nk
cell
ctl
tumor
tissu
make
profession
apc
ideal
candid
target
induc
antitumor
respons
human
dc
infiltr
vast
rang
tumor
includ
skin
cancer
ovarian
carcinoma
lung
colorect
cancer
howev
infiltr
lead
conclus
role
prognosi
infiltr
pdc
breast
cancer
ovarian
carcinoma
correl
advers
prognost
outcom
wherea
infiltr
pdc
lung
cancer
correl
prognosi
particular
tolerogen
state
seem
import
dc
remain
inactiv
state
due
immunosuppress
environ
tumor
nevertheless
studi
shown
tumor
regress
upon
treatment
sever
tlr
agonist
cpg
imiquimod
stari
et
al
shown
upon
treatment
basal
cell
carcinoma
patient
imiquimod
mdc
pdc
recruit
tumor
site
express
cytotox
effector
molecul
mous
model
transplant
melanoma
treatment
imiquimod
led
tumor
clearanc
manner
depend
product
chemokin
cc
ligand
ccl
mast
cell
induc
massiv
recruit
pdc
skin
lead
pdcdepend
reduc
melanoma
growth
anoth
studi
treatment
human
basal
cell
carcinoma
imiquimod
result
tumor
regress
recruit
pdc
specif
lyse
tumor
cell
express
trail
receptor
traildepend
manner
mdc
express
granzym
b
fact
pdc
lyse
cell
express
indic
cell
capac
act
anticanc
effector
cell
therebi
show
potenti
target
tumor
clearanc
data
suggest
tumorinfiltr
dc
act
killer
cell
directli
involv
tumor
clearanc
recent
studi
demonstr
deplet
unactiv
pdc
orthotop
mammari
tumor
model
delay
tumor
growth
howev
model
intratumor
administr
agonist
led
pdcand
typeiifndepend
tumor
regress
find
point
janusfac
function
tumor
infiltr
pdc
suggest
function
larg
determin
context
activ
state
indirect
antitumor
activ
killer
dc
via
amplif
adapt
immun
respons
past
decad
clinic
trial
carri
investig
worldwid
shown
vaccin
dc
load
ex
vivo
tumor
peptid
induc
tumorspecif
immun
respons
patient
advanc
cancer
howev
clinic
result
obtain
far
rather
disappoint
minor
treat
patient
show
longlast
clinic
respons
mani
research
effort
current
undertaken
improv
clinic
efficaci
dcbase
cancer
immunotherapi
protocol
thu
far
virtual
clinic
trial
base
ex
vivo
gener
dc
either
deriv
monocyt
progenitor
cell
recent
possibl
explor
exploit
scarc
natur
circul
dc
pdc
vaccin
endstag
melanoma
patient
show
promis
result
term
overal
surviv
sever
research
group
demonstr
human
killer
dc
apart
direct
tumoricid
activ
present
tumor
antigen
cell
provid
strong
rational
use
killer
dc
dcbase
vaccin
protocol
ifna
differenti
modc
found
effici
stimul
antigenspecif
cell
respons
human
pdc
also
capac
present
antigen
potent
stimul
cell
respons
high
effector
target
ratio
requir
detect
kill
activ
argu
favor
predomin
role
dc
acquisit
present
antigen
rather
role
effector
cell
capabl
kill
tumor
virusinfect
cell
review
recent
studi
provid
evid
effector
role
dc
cytolysi
propos
dc
pdc
particular
present
promis
target
immunotherapi
infiltr
tumor
lesion
upon
activ
capabl
specif
kill
tumor
cell
either
directli
via
activ
cytotox
effector
cell
howev
mani
question
remain
killer
dc
figur
indirect
cytotox
human
killer
dc
subset
antigenload
killer
dc
abil
activ
antigenspecif
cytotox
cell
turn
lyse
target
cell
whether
killer
dc
also
abil
crosspres
antigen
obtain
kill
target
cell
thereaft
crossprim
cytotox
cell
unclear
furthermor
human
pdc
produc
larg
amount
type
ifn
upon
stimul
next
direct
cytotox
effect
exert
indirect
cytotox
effect
activ
nk
cell
ii
enhanc
antigen
crosspresent
crossprim
cell
iii
gener
ifnainduc
killer
modcsmdc
abbrevi
cpg
cpg
oligodeoxynucleotid
dc
dendrit
cell
flu
influenza
fsme
h
sommer
meningoenceph
human
immunodefici
viru
htlv
human
lymphotrop
viru
ifn
interferon
nk
natur
killer
tbev
tickborn
enceph
viru
trend
immunolog
januari
vol
use
full
capac
clinic
situat
exactli
killer
dc
recogn
tumortarget
cell
particular
mhcclassineg
cell
exact
mechan
dc
use
exampl
exclus
trail
mechan
furthermor
human
killer
dc
crosspres
antigen
deriv
kill
target
cell
answer
question
may
help
exploit
killer
dc
immunotherapi
